Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-infectives - EPIRUS Biopharmaceuticals

Drug Profile

Research programme: anti-infectives - EPIRUS Biopharmaceuticals

Alternative Names: CRx-808

Latest Information Update: 01 Aug 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CombinatoRx
  • Developer EPIRUS Biopharmaceuticals; National Institute of Allergy and Infectious Diseases; United States Army Medical Research Institute of Infectious Diseases
  • Class Small molecules
  • Mechanism of Action Anthrax toxin inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alphavirus infections; Anthrax; Ebola virus infections; Hepatitis B; Hepatitis C

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 17 Jul 2014 No development reported - Preclinical for Alphavirus Infections in USA (unspecified route)
  • 17 Jul 2014 No development reported - Preclinical for Anthrax in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top